false
OasisLMS
Catalog
SCCM Resource Library
Clostridioides difficile Guidelines
Clostridioides difficile Guidelines
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Ramsey Rimawi discusses updates on Clostridioides difficile (C. diff) infection. Despite a decrease in the incidence of C. diff, it remains a problem in ICU patients. The causes of C. diff include antibiotics, chemotherapy, inflammatory bowel disease, and more. Testing methods have remained relatively unchanged, with nucleic acid amplification tests being the preferred choice. Repeat testing within a seven-day period is no longer necessary. In terms of treatment, fidaxomicin has become the preferred drug, while vancomycin is an alternative. Other drugs, such as tigecycline and oxazolidinones, have shown mixed results. Fecal microbiota transplant and benzalotoximab are options for recurrent C. diff infections. Prevention methods such as proton pump inhibitors and probiotics have insufficient data. Overall, the 2021 guidelines provide updated recommendations for managing and treating C. diff infection.
Asset Subtitle
Infection, Quality and Patient Safety, 2023
Asset Caption
Type: two-hour concurrent | Updates on Infectious Disease Guidelines in Critical Care (SessionID 1229708)
Meta Tag
Content Type
Presentation
Knowledge Area
Infection
Knowledge Area
Quality and Patient Safety
Membership Level
Professional
Membership Level
Select
Tag
Infectious Diseases
Tag
Guidelines
Year
2023
Keywords
Clostridioides difficile infection
ICU patients
antibiotics
nucleic acid amplification tests
fidaxomicin
×
Please select your language
1
English